NSAID-induced gastrointestinal and cardiovascular injury

Current Opinion in Gastroenterology

Volumn 26, Issue 6, 2010, Pages 611-617

  Ng, Siew C ^a   Chan, Francis K L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

aspirin; clopidogrel; cyclooxygenase 2 inhibitors; gastrointestinal bleed; nonsteroidal anti inflammatory drugs; peptic ulcers

Indexed keywords

ACETYLSALICYLIC ACID; BILE ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; ROFECOXIB;

ACUTE CORONARY SYNDROME; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MEMBRANE; CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG METABOLISM; DUODENUM ULCER; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; TICLOPIDINE;

EID: 77958484639     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32833e91eb     Document Type: Review

References (55)

1. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124:288-292.
2. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117:2104-2113.
3. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29:481-496.
4. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008; 134:937-944.
5. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621-1626.
6. Blandizzi C, Tuccori M, Colucci R, et al. Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic nonsteroidal antiinflammatory therapy. Pharmacol Res 2009; 59:90-100.
7. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374:1449-1461.
8. Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol 2009; 54:309-317.
9. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728-738.
10. Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62:1592-1601.
11. Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007; 132:490-497.
12. Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009; 48:425-432.
13. Zhou Y, Lichtenberger LM. Nonsteroidal anti-inflammatory drugs alter lateral distribution within epithelial cell plasma membrane. Gastroenterology 2010; 138 (Suppl 1):T1136
14. NSAIDs induce profound changes in the epithelial cell plasma membrane, which may be involved in both the biological actions and cytotoxicity associated with these drugs.
15. Hampton D, Hale LP. Mast cells are critical for prevention of NSAID-induced gastric ulceration. Gastroenterology 2010; 138 (Suppl 1):772.
16. Shiotani A, SakakibaraT, Nishi R, et al. Renin-angiotensin system and risks of peptic ulcer and ulcer bleeding induced by low dose aspirin. Gastroenterology 2010; 138 (Suppl 1):774.
17. Bjarnason I, Hayllar J, Macpherson AJ, et al. Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104:1832-1847.
18. Chan FK, Cryer B, Goldstein JL, et al. A novel composite endpointto evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010; 37:167-174.
19. Lanas A, Osenenko K, Medin J, et al. A systematic review of the risk of upper gastrointestinal complications among patients on low-dose aspirin with additional risk factors. Gastroenterology 2010; 138 (Suppl 1):T1146.
20. Yuan YH, Wang C, Yuan Y, et al. Meta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials. Aliment Pharmacol Ther 2009; 30:197-209.
21. Huang ES, Strate LL, Ho WW, et al. Long term use of aspirin and risk of gastrointestinal bleeding in a prospective, population-based cohort. Gastroenterology 2010; 138 (Suppl 1):475e.
22. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22.
23. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21:1411-1418.
24. Hawkey CJ, Wilson I, Naesdal J, et al. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in nonsteroidal antiinflammatory drug users. Gut 2002; 51:344-350.
25. Hart J, Hawkey CJ, Lanas A, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2010; 31:143-149.
26. Okada K, Inamori M, Imajyo K, et al. Gender differences of low-dose aspirin-associated gastroduodenal ulcer in Japanese patients. World J Gastroenterol 2010; 16:1896-1900.
27. Lanas A, Armada B. Gastrointestinal and cardiovascular risk profile of osteoarthritis patients receiving NSAID: the Jornada Study. Gastroenterology 2010; 138 (Suppl 1):W1013.
28. Lanas A, Tornero J, Zamorano J, et al. Over half of patients with osteoarthritis requiring NSAID therapy are at either high GI or CV risk. Gastroenterology 2010; 138 (Suppl 1):T1138.
29. Laine L, Connors L, Griffin MR, et al. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther 2009; 30:767-774.
30. Chan FK, Scheiman JM, Lanas A, et al. Celecoxib versus diclofenac and omeprazole: a randomised controlled trial comparing a composite outcome across the entire GI tract (The Condor Trial). Lancet 2010; 376:173-179.
31. Cheung R, Cheng TT, Dong Y, et al. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis 2010; 13:151-157.
32. Nakashima S, Ota S, Arai S, et al. Usefulness of antiulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J Gastroenterol 2009; 15:727-731.
33. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:119-125.
34. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334:1435-1439.
35. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastro enterology 2010; 138:82-88.
36. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
37. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1-9.
38. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118:1894-1909.
39. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.
40. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180:713-718.
41. Kreutz RP, StanekEJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 2010; 30:787-796.
42. Dunn SP, Macaulay TE, Brennan DM. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation 2008; 118:S815.
43. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374:989-997.
44. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373:309-317.
45. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events.NEngl J Med 2009; 360:363-375.
46. Ramirez JF, Selzer F, Chakaprani R. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol 2009; 53:A27.
47. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256-260.
48. US Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). http://www.fda. gov/Drugs/DrugsSafety/ucm079520.htm. [Accessed May 2009]
49. US Food and Drug Administration. Plavix (clopidogrel bisulfate) 75 mg tablets. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm165166.htm. [Accessed May 2009]
50. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Plavix/32895609en.pdf. [Accessed May 2009]
51. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105:34-41.
52. Bhatt DL, Cryer B, Contant CF. COGENT: a Prospective, Randomised, Placebo-Controlled Trial of Omeprazole in patients receiving aspirin and clopidogrel. Transvascular Cardiovascular Therapeutics Annual Meeting; 2009.
53. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152:337-345.
54. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008; 43:270-276.
55. Shiotani A, Haruma K, Nishi R, et al. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin: low-dose aspirin-induced small bowel damage. Scand J Gastroenterol 2010; 45:292-298.